Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic/Recurrent Breast Cancer
Interventions: DRUG: Tesmilifene (YMB 1002)
Sponsor: YM BioSciences